These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 28476806)
1. Fibronectin and Hepatocyte Growth Factor Produced by Lung Fibroblasts Augment Migration and Invasion of Malignant Pleural Mesothelioma Cells. Kanaji N; Kita N; Kadowaki N; Bandoh S Anticancer Res; 2017 May; 37(5):2393-2400. PubMed ID: 28476806 [TBL] [Abstract][Full Text] [Related]
2. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Jagadeeswaran R; Ma PC; Seiwert TY; Jagadeeswaran S; Zumba O; Nallasura V; Ahmed S; Filiberti R; Paganuzzi M; Puntoni R; Kratzke RA; Gordon GJ; Sugarbaker DJ; Bueno R; Janamanchi V; Bindokas VP; Kindler HL; Salgia R Cancer Res; 2006 Jan; 66(1):352-61. PubMed ID: 16397249 [TBL] [Abstract][Full Text] [Related]
3. Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. Li Q; Wang W; Yamada T; Matsumoto K; Sakai K; Bando Y; Uehara H; Nishioka Y; Sone S; Iwakiri S; Itoi K; Utsugi T; Yasumoto K; Yano S Am J Pathol; 2011 Sep; 179(3):1483-93. PubMed ID: 21763682 [TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression. Kanaji N; Yokohira M; Nakano-Narusawa Y; Watanabe N; Imaida K; Kadowaki N; Bandoh S Respir Res; 2017 Jun; 18(1):118. PubMed ID: 28619066 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Suzuki Y; Sakai K; Ueki J; Xu Q; Nakamura T; Shimada H; Nakamura T; Matsumoto K Int J Cancer; 2010 Oct; 127(8):1948-57. PubMed ID: 20104519 [TBL] [Abstract][Full Text] [Related]
6. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma. Meerang M; Bérard K; Felley-Bosco E; Lauk O; Vrugt B; Boss A; Kenkel D; Broggini-Tenzer A; Stahel RA; Arni S; Weder W; Opitz I Mol Cancer Ther; 2016 May; 15(5):1095-105. PubMed ID: 26839306 [TBL] [Abstract][Full Text] [Related]
7. Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent. Jagirdar RM; Apostolidou E; Molyvdas PA; Gourgoulianis KI; Hatzoglou C; Zarogiannis SG Am J Physiol Lung Cell Mol Physiol; 2016 Mar; 310(6):L489-95. PubMed ID: 26773069 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of the met receptor in mesothelioma. Mukohara T; Civiello G; Davis IJ; Taffaro ML; Christensen J; Fisher DE; Johnson BE; Jänne PA Clin Cancer Res; 2005 Nov; 11(22):8122-30. PubMed ID: 16299245 [TBL] [Abstract][Full Text] [Related]
9. Cell and extracellular matrix interaction models in benign mesothelial and malignant pleural mesothelioma cells in 2D and 3D in-vitro. Jagirdar RM; Papazoglou ED; Pitaraki E; Kouliou OA; Rouka E; Giannakou L; Giannopoulos S; Sinis SI; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG Clin Exp Pharmacol Physiol; 2021 Apr; 48(4):543-552. PubMed ID: 33336399 [TBL] [Abstract][Full Text] [Related]
10. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Ikuta K; Yano S; Trung VT; Hanibuchi M; Goto H; Li Q; Wang W; Yamada T; Ogino H; Kakiuchi S; Uehara H; Sekido Y; Uenaka T; Nishioka Y; Sone S Clin Cancer Res; 2009 Dec; 15(23):7229-37. PubMed ID: 19934291 [TBL] [Abstract][Full Text] [Related]